乌司奴单抗围受孕期或妊娠期暴露后的妊娠结局:制造商全球安全性数据库病例回顾
该研究基于制造商全球安全性数据库,汇总截至2020年8月31日经医学确认的408例母亲乌司奴单抗暴露的前瞻性妊娠数据,报告活产340例(81%)、自然流产51例(12.1%)等结局,主要先天畸形率在不同适应症、剂量及暴露时机间相似,结论认为不良妊娠结局或先天畸形率与美国一般人群报告率一致,不提示母体或父体暴露增加风险。
要点
- 408例母亲乌司奴单抗暴露妊娠中,活产340例(81%),自然流产51例(12.1%)。
- 340例活产中33例(9.7%)为早产。
- 主要先天畸形率在克罗恩病与银屑病、45 mg与90 mg剂量及暴露时机和持续时间间相似。
核心结论
- 乌司奴单抗暴露的不良妊娠结局或先天畸形率与美国一般人群报告率一致,不提示母体或父体暴露增加风险。
研究设计与样本
- 基于制造商全球安全性数据库,汇总截至2020年8月31日经医学确认的乌司奴单抗暴露妊娠的前瞻性数据,进行描述性总结。
主要发现
- 共识别408例经医学确认、有结局报告的母亲乌司奴单抗暴露前瞻性妊娠,平均母亲年龄31岁。
- 420例妊娠结局(含4对双胞胎)中,活产340例(81%)、自然流产51例(12.1%)、选择性/人工流产25例(6%)、死产3例(0.7%)、持续妊娠伴胎儿先天畸形1例(0.2%)。
- 340例活产中33例(9.7%)为早产。
- 主要先天畸形率在克罗恩病与银屑病、乌司奴单抗45 mg与90 mg剂量及母体暴露时机和持续时间间相似。
- 父体围受孕期乌司奴单抗暴露的前瞻性妊娠结局(n=87)包括活产92%(主要先天畸形1.2%)、自然流产5.7%、选择性/人工流产2.3%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ustekinumab, a human immunoglobulin G1 monoclonal antibody that binds to and inhibits interleukin (IL)-12/IL-23, is indicated for multiple immune-mediated diseases. Ustekinumab is actively transported across the placenta and theoretically could impact pregnancy outcomes. Limited data on pregnancy outcomes with ustekinumab exposure are available. AIM: To assess pregnancy outcomes in patients exposed to ustekinumab during pregnancy METHODS: Cumulative data on medically confirmed ustekinumab-exposed pregnancies from the manufacturer's Global Safety Database were summarised. Descriptive data for pregnancy outcomes were presented overall and by patient subgroups. RESULTS: As of 31 August 2020, 408 medically confirmed, prospective, maternal ustekinumab-exposed pregnancies with reported outcomes were identified. The mean maternal age was 31 years. Of the 420 pregnancy outcomes (including 4 sets of twins),a , b 340 (81%) were live births, 51 (12.1%) spontaneous abortions, 25 (6%) elective/induced abortions, 3 (0.7%) stillbirths and 1 (0.2%) ongoing pregnancy with foetal congenital anomaly (CA). Among 340 live births, 33 (9.7%) were born pre-term. The rate of major CAs was similar by indication (Crohn's disease vs psoriasis), ustekinumab dose (45 mg vs 90 mg) and timing and duration of maternal exposure to ustekinumab. Prospective outcomes of pregnancies with paternal periconceptional ustekinumab exposure (n = 87) included 92% live births (1.2% major CA), 5.7% spontaneous abortions and 2.3% elective/induced abortions. CONCLUSIONS: Rates of adverse pregnancy outcomes or CAs with ustekinumab exposure were consistent with rates reported for the US general population and do not suggest a higher risk associated with maternal or paternal exposure to ustekinumab.
引用
- Mahadevan U, Naureckas S, Tikhonov I, et al. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database. Aliment Pharmacol Ther. 2022. PMID: 35560249. doi:10.1111/apt.16960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。